



ANNOUNCEMENT INDIA-EU COOPERATION ON RESEARCH & INNOVATION (R&I)

DBT ANNOUNCES CO-FUNDING PARTNERSHIP UNDER THE EU FRAMEWORK PROGRAMME ON R&I 'HORIZON EUROPE' CALLS 2023-2024

Collaboration in Science, Technology and Innovation (STI) plays an increasingly important role in the EU-India Strategic Partnership. In line with the EU-India Strategic Partnership: A Roadmap to 2025, and the Joint Science and Technology Steering Committee meeting on 12 February 2021, the Department of Biotechnology (DBT), has identified calls for proposals in the Work programmes 2023-2024 of the EU R&I Research and Innovation Programme 'Horizon Europe', which it considers of mutual interest and aiming at jointly tackling global challenges.

For this, DBT has established a mechanism outlining the conditions upon which it will co-fund the successful Indian entity/ies and in which call topics (hereafter Co-Funding Mechanism or CFM).

The CFM will apply to the call topics earmarked by DBT in areas of **pandemic preparedness and response, brain disorders, biofuels and healthy & environmentally-friendly food.** This notice explains in the different Sections hereunder how to prepare and submit a co-funded project.

In **Section 1** the **five call topics** earmarked by DBT for co-funding are listed. The list indicates the exact Call IDs, the opening and closing date of the call, the type of action provided and the link to the full call text as published in the Horizon Europe Funding & Tenders Portal.

In Sections 2 and 3, the various modalities of participation that the Indian applicants have to comply with, including the Administrative and Financial Considerations (see Annex 1) is outlined.

All proposals have to be submitted to **both** the Horizon Europe Funding & Tenders Portal and to DBT. The EU will only evaluate the proposal submitted to its portal. DBT expects to receive the same copy with in addition all details on the budget the Indian entity requires for its participation. Budget information to be provided in prescribed format and in Indian Rupees. In the absence of this, DBT will disqualify the Indian participants from funding (see **Section 4** hereunder).

At the end of the notice, information is provided on how to access and go about

'Horizon Europe' formalities, which also Indian applicants have to comply with (Annex 2) and on how to find partners (Annex 3).

For the complete call text click Horizon Europe Funding & Tenders Portal including the general conditions and modalities, and in particular the specific call conditions on the given call topic. Please read carefully the call text itself, which is the only legally binding text.

CONTENT

SEC	CTION	1: LIST OF CO-FUNDED CALL TOPICS4
SEC		2: MODALITIES OF PARTICIPATION & FUNDING FOR INDIAN LICANTS
1.	PAR	ГІСІРАТІОN6
	1. 1.	Participation of Indian6
	1. 2.	Participation of European
	1.3.	Gender Balance8
2.	ELIC	GIBILITY8
	2.1.	Indian Entities Eligible to Participate8
	2.2.	European Entities Eligible to Participate8
3.	FUN	DING9
	3.1	Funding by DBT9
	3.2	Funding by EU9
	3.3	IPR: Ownership, Protection & User rights
4.	PRE	EPARATION OF PROPOSAL10
SEC	CTION	3: REGULATORY & ETHICAL CONSIDERATIONS (IF APPLICABLE) 13
	1.	Notifications/ Orders issued towards expeditious consideration of various regulatory aspects in response to COVID-19 pandemic
	2.	Research using hazardous microorganisms, genetically engineered (GE) organisms & products thereof for R&D purpose13
	3.	Human and Animal Subjects Research14
	4.	Authorizations for pre-clinical and/or human clinical trials14
SEC	CTION	4: PROCESS FOR SUBMISSION OF PROJECT PROPOSAL14
	1.	Submission of proposal on Horizon Europe Funding & Tenders Portal15
	2.	Submission to DBT of the proposal including budget requested from DBT15
	3.	Submission to Horizon Europe Funding & Tenders Portal16
		R INFORMATION16
ANI	NEX 1	: TEMPLATES FOR ADMINISTRATIVE & FINANCIAL CONSIDERATIONS
ANI	NEX 2	: HOW TO ACCESS HORIZON EUROPE PORTAL & FORMALITIES22
ANI	NEX 3	: FINDING PARTNERS23

SECTION 1: LIST OF CO-FUNDED CALL TOPICS

The CFM applies only to the call topics in HE Work Programme 2023-2024 listed hereunder:

S. NO.	Title	Topic Identifier	Type of Action	Opening Date	Closing Deadline			
	HEALTH							
1.	Pandemic preparedness and response: Broad spectrum antiviral therapeutics for infectious diseases with epidemic potential	HORIZON-HLTH- 2023-DISEASE-03- 04	RIA	12 Jan 2023	13 Apr 2023			
2.	 Proposals should address all of the feature of the fe	oof-of-concept/first-ing new or improved thway. Phase IIb/III pems and suitable safe. Attention should be conomic factors, ethniproaches and widely and reliable identore	anti-vira chase trial ety profi e paid to icity/migr applicab	I therapeut Is will not b les for broa critical soci ation, and c ole workflo	ics, with a clear se supported. ad use should be al factors such as lisability. ws (e.g. artificial			
	biomarkers for the prediction and prevention of brain disorders Proposals should address all of the formula of the proposals should aim to proposal s	2024-DISEASE-03- 13-two-stage Collowing aspects: alidate biomarkers that uide treatment/ interver provide evidence supp a, biobanks, registries a cient organisations in the considered. ge, socio-economic, lifthe study. uples, quality data and de for using infrastructurent ent of brain disorde	can relial ation selectoring the and cohort the research estyle and advance tures alreaders, considers, considers	oly confirmation. regulatory s is expected h is strongly behavioura d analytical ly developed	(First Stage), 11 Apr 2024 (Second Stage) early stages of the acceptance of the d, together with the r encouraged, as to l factors should be and digital tools, at the European or			
3.	Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential Proposals should address several of Identification and character internalisation of a virus	isation of receptors on			_			

receptors and tissue specificity.

- Identification and characterisation of viral surface proteins that are capable of interacting with host target cells.
- Characterisation of the mechanism of viral uptake in the host cell with regard to the topology and the dynamics of the host receptor virus ligand interaction.
- Identification of receptor and ligand (sub)units that could be targeted by preventive or therapeutic intervention. Read More

HEALTHY AND ENVIRONMENTALLY-FRIENDLY FOOD 12 Apr 2023 methods HORIZON-CL6-RIA 22 Dec New detection on products derived from new 2023-2022 genomic FARM2FORK-01techniques for traceability, transparency and <u>11</u> innovation in the food system

Proposals are expected to contribute to the development and validation of detection methods of products obtained through new genomic techniques, including all of the following activities:

- Examine innovative ways and/or specific markers that would allow for distinction between products resulting from new genomic techniques subject to the GMO legislation and products that are not subject to the GMO legislation. This should not only entail the detection of specific mutations, but also of other markers in the genome that are specific for the genotype containing the mutation/s. The methods should be able to distinguish between identical mutations obtained through different techniques;
- Development and validation of reliable detection methods including when possible quantification. Such methods could focus on products with known mutations (i.e. DNA sequence known) or on products with unknown mutations;
- The proposed detection methods should focus on a wide applicability of all or a subgroup of
 products, allowing for a screening approach. These methods should be assessed on pure products
 as well as on mixtures typical of food or feed products in the market. Proposals should always
 include plant-based products and may include also animal and/or microorganisms-based
 products.
- The proposal could also focus on the detection of unintended mutations or insertions (foreign DNA, CRISPR-Cas sequences, etc);
- The proposals could also include digital/virtual/AI modelling aspects along with the detection methods alternatives;
- The development and validation of standardized methodologies and the contribution to future standardisation processes is encouraged. Read More

		BIOFUELS			
5.	Development of smart	HORIZON-CL5-	RIA	17	04 February
	concepts of integrated energy	2024-D3-02-03		September	2025
	driven bio-refineries for co-			2024	
	production of advanced				
	biofuels, bio-chemicals and				
	biomaterials				

Proposals should address several of the following areas:

- Development of zero-waste and neutral or negative carbon emission energy-efficient biorefinery concepts for enabling the production of low-cost advanced biofuels through co-production of added value bio-based products and bioenergy.
- Conversion of biogenic wastes and residues as well as algae and aquatic biomass through chemical, biochemical, electrochemical, biological, thermochemical pathways or combinations of them in highly circular processes are in scope.
- Technology validated in relevant environment is required. International cooperation with **Mission Innovation countries is expected**.
- Proposals should provide information and assessment about the economic feasibility and the potential of scaling-up the technology at commercial scale as appropriate. Read More

NOTE: DBT will support projects for development and demonstration of zero waste integrated biorefinery with focus on <u>agriculture wastes/residues as well as algae and aquatic</u> biomass.

To note that the type of collaborative actions, Research and Innovation (RIA) and Innovation Actions (IA) are established by Horizon Europe, and to be understood as follows:

- **Research & innovation action (RIA)** that establishes new knowledge or explores a new or improved technology, product, process, service or solution.
- Innovation action (IA) that produces plans or designs for new or improved products, processes or services including prototyping, testing, demonstrating, piloting, large-scale product validation and market replication.

Technology Readiness Levels

Where the specific call conditions require a Technology Readiness Level (TRL), the following definitions apply, unless otherwise specified:

- TRL 1 Basic principles observed
- TRL 2 Technology concept formulated
- TRL 3 Experimental proof of concept
- TRL 4 Technology validated in a lab
- TRL 5 Technology validated in a relevant environment (industrially relevant environment in the case of key enabling technologies)
- TRL 6 Technology demonstrated in a relevant environment (industrially relevant environment in the case of key enabling technologies)
- TRL 7 System prototype demonstration in an operational environment
- TRL 8 System complete and qualified
- TRL 9 Actual system proven in an operational environment (competitive manufacturing in the case of key enabling technologies, or in space)

SECTION 2: MODALITIES OF PARTICIPATION & FUNDING FOR INDIAN APPLICANTS

1. PARTICIPATION

1. 1. Participation of Indian

Participation entity in Horizon Europe projects

• Eligibility of Indian entities is defined by DBT.

- Since the Indian entity is not receiving funding from the EU under Horizon Europe, it is not required to sign the EU Grant Agreement. It will participate as "Associated Partner" and mentioned as such in Article 9.1 of the EC grant Agreement.
- This means that the Indian entity is expected to contribute to the smooth implementation of the project as specified in the consortium agreement.

Formality for Participation

• If you want to participate in a Horizon Europe project proposal, your organisation needs to be registered in the Participant Register of the Funding & Tenders Portal and have a 9-digit Participant Identification Code (PIC) number (see registration procedure in Annex 2)

Number of Indian entities per projects

- There is no legal requirement on number of Indian entities in a given project eligibility condition. Any legal entity/organization (public or private research institute/university) established in India with expertise in relevant and distinct disciplines. No limit on number of Indian participants but each partner should be necessary for the execution of the project and comply with the eligibility conditions. The scientific R&D performing Indian industry may participate voluntarily in this call with participating Indian industry investing its own resources or come in collaboration with research/academic organization, but by investing their own resources (see section 2).
- The call is open to all career groups (i.e. early, intermediate and senior); however, it is expected that each investigator shall have adequate service tenure to accommodate key research, coordination, outreach, post completion handholding and maintenance (if any) responsibilities. Early career investigators are encouraged to participate.
- Each participating legal entity/organisation (public or private research institute/university) should be represented by at least two investigators.
- The number of Indian project partners should be optimum and correspond to the objectives of the project. The proposal should clearly demonstrate each partner's essentiality, complementarities, and added-value in jointly addressing the topic.
- In case there is more than one Indian legal entity/organization participating in a given project, it is advised that the Indian participants appoint among them a 'Lead Scientific Coordinator-INDIA', who can represent the Indian participants in the consortium vis-à-vis DBT. To ensure continuity in the project, at least two investigators must represent each participating legal entity/organization.

1. 2. Participation of European

Number of European entities per projects

- Collaborative research & innovation projects carried out by consortia of organisations working together on specific research & innovation areas. A consortium must include at least 3 partner organisations from 3 different Member States or associated countries. At least one of the 3 partners must be from Member States.
- European Union member states (EU27): Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.

- Countries Associated with Horizon Europe: Agreements in place: Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, North Macedonia, Norway, Serbia, Tunisia, Turkey and Ukraine.
- The EU is still in the process of association negotiations with Morocco, New-Zealand and United Kingdom's (UK) - See updates updated¹ - HE association agreements status as of 15.01.2023
- In addition to these three partners, any legal entity from anywhere in the world can be included in the consortium. Please consult the Horizon Europe programme guide².

1.3. Gender Balance

Applicants are encouraged to promote equal opportunities in the implementation of the action by ensuring a balanced participation of women and men at all levels of the research and innovation teams and in the management structures.

2. ELIGIBILITY

The participating entities/organisations from India have to be a legal entity as per Indian law (Indian applicants) and the European entities as per the <u>Horizon Europe rules of participation</u>.

2.1. Indian Entities Eligible to Participate

• Government of India supported or recognised Public or Private academia and research organisations (research institutes & universities);

Indian entities

Academic/Research Partners:

- O Public and/or private universities and research organisations must have a well-established research support system, for basic or applied research; and
- Submission of proof of establishment under Indian statue; recognition documents and registration at Government of India's Public Finance Management System (PFMS) -https://pfms.nic.in shall be obligatory.

Ineligible organisations:

 Research centres and academic organisations headquartered and owned outside India and their subsidiaries in India, or vice versa, are not eligible to receive funding from DBT under this programme.

2.2. European Entities Eligible to Participate

 Any legal entity is eligible to participate, provided that the conditions laid down in the Horizon Europe Regulation have been met, along with any other conditions laid down in the specific call topic³.

https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf

3. Funding

3.1 Funding by DBT

DBT will fund the Indian partners/entities in a successful project, as per requirement of the project, for the project duration up to 3-4 years.

Budget should be commensurate with the essentiality of participation, workload, objectives of the project and cost of participation.

3.1.1 Eligibility for Funding

Budgeted costs of the project to legal entities subject to obligatory fulfilment of eligibility criteria:

- DBT will support (Grant-in-aid) 100% of the approved budget costs to Government of India supported or recognised public or private academic institutions or research organisations;
- Eligible costs for funding are: Capital expenditure (equipment's) || Manpower || Consumables || Travel (local and international* travel) || Contingency || Overheads || Outsourcing || others. (Academia can factor in additional sub heads (in other category) such as training & awareness; workshops; publications; review meetings, etc. under expenditure based on the requirement of the project).
 - * The travel of investigator(s) and project staff (s) will be as per prevailing Government of India guidelines.

3.1.2 Non-Admissible Cost from DBT

- **i.** Prosecution/litigation costs;
- ii. Salary of investigators;
- **iii.** Capital expenditure for the purchase of assets such as office furniture, motor vehicles, Office equipment viz. desktops, laptops, tablets, cell phones, scanners, printers, photocopy machines, and renovation or extension of facilities such as buildings and laboratories;
- iv. Capital expenditure toward technology(ies), demonstration plants and associated field equipment(s), hardware, software etc. for test and analysis from consortium partner(s) from abroad;
- v. Expenditure toward rental and utilities;
- **vi.** International travel to countries other than the one participating within the consortia in a particular call topic of Horizon Europe;
- vii. Mere attendance at conferences/ symposiums/ congresses

3.2 Funding by EU

Funding of European partners is as per Horizon Europe rules of participation and in function of type of action [RIA & IA]⁴.

https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf (page 5)

https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf

3.3 IPR: Ownership, Protection & User rights

- IPR legislation and other rules are often crucial for participants in research projects, as they may have a deep influence on the way in which the knowledge can be shared during a project development, and in which project results can be commercially used.
- The participants shall jointly develop a Consortium Agreement (CA). The CA is a specific agreement to be concluded between the participants in joint research, defining, among other things, ownership, protection, user rights for research and development purposes, exploitation and dissemination, including arrangements for joint publication, the rights and obligations of visiting researchers and dispute settlement procedures. The CA shall also address foreground and background information, licensing and deliverables.
- The IPR issues for all the proposals need to satisfy the S&T agreement between EU and India

4. PREPARATION OF PROPOSAL

The Indian and European participants must formulate a joint proposal, according to the requirements and <u>templates</u> provided by respectively Horizon Europe Funding & Tenders Portal format⁵ and DBT's administrative and financial requirements (see annex 1). Complying with the formats and templates of Horizon Europe and DBT for the Indian partners is mandatory. Indian entities should participate as an **Associated Partners**.

The Horizon Europe proposal consists of two main parts:

- Part A: the Administrative Forms containing general information on the project (title, abstract, and keywords), the consortium (basic administrative data, contact persons, declarations) and the budget overview.
- **Part B**: the **Technical Annex** containing the detailed description of the planned research and innovation project. The structure is based on the evaluation criteria (cite them here) as provided in the proposal template for a RIA/IA.


How to Add Associated Partners to a Proposal on the Funding & Tenders Portal


Entities based in India can participate to Horizon Europe projects by applying under the participant role of "Associated Partners" (AP).


This is a step-by-step guide on (to be done via European proposal coordinator):

- o how to add an AP to a proposal on the Portal
- o how to include the budget of an AP on the Portal
- o how to deal with the budget table for Lump Sum projects

⁵ https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af he-ria-ia en.pdf







"Financial Contribution". Insert here the total amount that the Indian entity participating as an AP intends to request to DBT.

In general, this budget category is used for any financial contribution expected to be received/ already received from other sources for being used specifically for the same action as the one submitted for funding under Horizon Europe (e.g. funding from DBT).

Tasks attributed to the Associated Partner must be described in the technical description (Part B) of the project. If you wish, you can also include in this section the estimated budget of the entity (not mandatory).

Indian participants prepare budget (in Rupees) according to DBT requirements and templates

- Indian participants **MUST** submit detailed financial plan in **Indian Rupees** (₹) for duration of the project to DBT only.
- The detailed Indian financial plan for each Indian participant in the project must be specified according to format provided by DBT in <u>Annex 1</u>: Indian academic partners must use "Budget Format Academic Partner" (at para 7.2).

DBT's budget calculation for Indian participants

Indian participant must ensure that each Indian participant follows budget format proposed by the DBT.

Direct Costs:

- 1) **Manpower cost**: as per the requirements of the project (emoluments will be as per prevailing Gov. of India norms);
- 2) **Mobility of investigator(s) & project staff(s):** for visit(s) and work related to the project to be undertaken by Indian investigator(s) & project staff(s) **in Europe,** the cost of travel and man-days of stay in European countries (i.e. round-trip international travel by economy class, admissible insurances, local transport, boarding and lodging) must be justifiably budgeted by respective Indian organisation for each year, at 7.1 and 7.2 (as applicable) of <u>Annex 1.</u> The travel of investigator(s) and project staff (s) will be as per prevailing Government of India guidelines.
 - Institution hosting the collaborating investigator(s) & project staff(s) of other consortium participants, shall provide research facility and research resources to accomplish defined objectives and if required, this can be reflected in each participant budget adequately.
- 3) Overhead/Indirect Cost: overhead expenses payable to legal entity/organization for Indian partners, up to 10% of the total project cost for educational institutions and up to 8% for laboratories and institutions under central Government Departments/Agencies as per prevailing Gov. of India norms.

||to be noted ||

- Indian entity(ies) will submit detailed financial plan in Indian Rupees only to DBT
- The budget that DBT provides to Indian participants does not cover expenses incurred by the European and other countries' applicants in the consortium.
- Indian entity(ies) will <u>not sign EC's Grant Agreement</u> but considered as '<u>Associated Partners</u>'.

SECTION 3: REGULATORY & ETHICAL CONSIDERATIONS (IF APPLICABLE)

1. Notifications/ Orders issued towards expeditious consideration of various regulatory aspects in response to COVID-19 pandemic

- Rapid Response Regulatory Framework for COVID-19 to deal with applications for development of Vaccines, Diagnostics, Prophylactics and therapeutics
 - → http://dbtindia.gov.in/sites/default/files/uploadfiles/om_covid19%20April%202020.pdf
- Interim Guidelines on Laboratory Biosafety to Handle COVID-19 Specimen for R&D Purpose
 - → https://ibkp.dbtindia.gov.in/Content/FlashPDF/OM_Interim_Guidance_COVID.pdf
- Rapid Response Regulatory Framework for COVID-19 Vaccine Development
 - → https://ibkp.dbtindia.gov.in/Content/FlashPDF/Checklist_Recombinant%20Vaccine%20_COVID%2019.pdf
- Guidelines for sharing of Bio-specimen and Data for Research related to COVID-19
 - → https://niti.gov.in/sites/default/files/2020-04/Guidelines-for-sharing-of-Biospecimen-and-data-for-research-related-toCOVID-19..pdf
- SOP Template for Ethics Review of Biomedical and Health Research During Covid-19 Pandemic, 2020
 - → http://ethics.ncdirindia.org//asset/pdf/SOP_Template_EC_COVID19.pdf
- National Guidelines for Ethics Committees Reviewing Biomedical & Health Research During Covid-19 Pandemic, 2020
 - → http://ethics.ncdirindia.org//asset/pdf/EC_Guidance_COVID19.pdf

2. Research using hazardous microorganisms, genetically engineered (GE) organisms & products thereof for R&D purpose

In India, research using hazardous microorganisms, genetically engineered (GE) organisms & products thereof are governed under Rules, 1989 (Rules for the Manufacture, Use/Import/Export and Storage of Hazardous Micro Organisms/ Genetically Engineered Organisms or Cells) of Environment (Protection) Act, 1986, according to which, necessary intimation/ recommendation/ authorization from concerned Institutional Biosafety Committee (IBSC), Review Committee on Genetic Manipulation (RCGM) & Genetic Engineering Appraisal Committee (GEAC) is obligatory based on type & scale of research operations.

Further guidance on regulatory considerations can be obtained from:

- Guidelines and Handbook for IBSCs, 2011 http://dbtindia.gov.in/sites/default/files/uploadfiles/Guidelines%20_Handbook_2011.pdf
- Regulations and Guidelines on Biosafety of Recombinant DNA Research & Biocontainment, 2017
 - http://www.dbtindia.nic.in/wp-content/uploads/Draft-Biosafety-Regulations-and-Biocontainment-Guidelines-2017-FF.pdf
- Recommendations for Streamlining the Current Regulatory Framework, 2005 http://www.moef.nic.in/divisions/csurv/geac/draftreport_rpharma.pdf

3. Human and Animal Subjects Research

DBT and the European Commission are committed to ensure that projects involving human or animal subjects are protected from research risks in compliance with the rules and policies in respectively the EU and India (ICMR/DBT policies).

All projects recommended for award that involve human or animal subjects will undergo Horizon Europe ethics review⁶ as well as a review by the Indian Bioethics Committees prior to award request.

For information on ICMR policies, please consult:

 Handbook on National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2018
 http://ethics.ncdirindia.org//asset/pdf/Handbook on ICMR Ethical Guidelines.pdf

India PIs of the consortium should apply to their institutional review boards (IRBs)/ institutional ethics committees (IECs) at the time of submission of proposal to obtain necessary bioethics approvals from all involved institutions.

4. Authorizations for pre-clinical and/or human clinical trials

While exploring vaccine developmental studies in India, Investigators must satisfy regulatory and ethical provisions adopted under:

- Drugs and Cosmetics Rules, 1945 (as amended from time to time) of Drugs and Cosmetics Act, 1940
- Committee for the purpose of Control and Supervision of Experiments on Animals. http://cpcsea.nic.in/Auth/index.aspx
- Schedule 'Y' of Drugs and Cosmetics Rules, 1945 || Requirements and Guidelines for Permission to Import and/or Manufacture of New Drugs for Sale or to undertake Clinical Trials: http://cdsco.nic.in/html/D&C_Rules_Schedule_Y.pdf
- Guidance for Industry on Preparation of Common Technical Document for Import/Manufacture and Marketing Approval of New Drugs for Human Use (New Drug Application-NDA):
 - http://www.cdsco.nic.in/writereaddata/CDSCO-GuidanceForIndustry.pdf
- Handbook: Good Laboratory Practice (GLP). Quality practices for regulated non-clinical research and development, 2nd ed. Geneva, World Health Organization, 2009 || http://www.who.int/tdr/publications/documents/glp-handbook.pdf
- Clinical Trials Registry of India (CTRI) India http://ctri.nic.in/Clinicaltrials/login.php

SECTION 4: PROCESS FOR SUBMISSION OF PROJECT PROPOSAL

All proposals with Indian applicants should be submitted to both Horizon Europe Funder & Tenders portal and to DBT.

opportunities/display/OM/Special+procedures%3A+Ethics+review%2C+security+scrutiny%2C+Ownership+control+check

⁶https://webgate.ec.europa.eu/funding-tenders-

1. Submission of proposal on Horizon Europe Funding & Tenders Portal

A joint proposals must be submitted electronically using the electronic submission system of the Funding & Tenders Portal⁷. This task will be done by designated European Project Coordinator. Please ensure he/she gets all the required information from Indian participant(s) on time. In preparation thereof, Indian applicants should have their Personal Identification Code (PIC). See Annex 2 hereunder. For more information, see <u>Proposal Submission Service User Manual</u>⁸.

2. Submission to DBT of the proposal including budget requested from DBT

The Indian participant(s) must submit the **complete proposal**, (Part A + Part B) and **same** as submitted on the Horizon Europe Funding & Tenders Portal), as one single consolidated PDF file + DBT's administrative and financial form to DBT **within 7 working days of closer of call deadline**.

	Pandemic preparedness and	HORIZON-HLTH-	
	response: Broad spectrum anti-viral	2023-DISEASE-03-	
	therapeutics for infectious diseases	<u>04</u>	
	with epidemic potential		
	Validation of fluid-derived	HORIZON-HLTH-	
	biomarkers for the prediction and	2024-DISEASE-03-	
	prevention of brain disorders	13-two-stage	icone@dbt.nic.in
(A)	Pandemic preparedness and	HORIZON-HLTH-	icone@ubt.mc.m
	response: Host-pathogen	2024-DISEASE-08-	
	interactions of infectious diseases	<u>20</u>	
	with epidemic potential		
	New detection methods on products	HORIZON-CL6-	
	derived from new genomic	2023-FARM2FORK-	
	techniques for traceability,	<u>01-11</u>	
	transparency and innovation in the		
	food system		
	Development of smart concepts of		
(D)	integrated energy driven bio-	2024-D3-02-03	
(B)	refineries for co-production of		balendra.singh@dbt.nic.in
	advanced biofuels, bio-chemicals		
	and biomaterials		

Please note that the proposal will be disqualified if not submitted to DBT to above indicated email ID by indicated date. Absence of timely submission or any discrepancy found in the proposal submitted at Horizon Europe Funding & Tenders Portal and to DBT will result in disqualification from consideration by DBT for funding.

After completion of HE peer review process, Indian participant(s) in shortlisted HE proposals will be requested to submit:

• A duly signed (<u>by the Lead Coordinator-INDIA</u>) and transmitted (<u>by the Utmost Authority of the organization</u>) short covering letter introducing the application, along with complete proposal to the concerned DBT contact point.

_

⁷ https://webgate.ec.europa.eu/funding-tenders-opportunities/pages/viewpage.action?pageId=1867927

⁸ https://ec.europa.eu/research/participants/data/support/sep_usermanual.pdf

• A comprehensive facts about administrative, statutory, ethical and financial considerations (including diligent justification for proposed budgetary requirements) in the form of checklist

3. Submission to Horizon Europe Funding & Tenders Portal

- In order to submit a proposal, any applicant (from Europe or India) needs to be registered by the European Commission and obtain for this purpose a Personal Identification Code also called PIC: see registration procedure in Annex 2).
- Online guidance is also provided on how to fill in the administrative forms (Part A).
- Proposal templates for the technical annex can be downloaded from the system. The technical annex and any additional annexes have to be uploaded as PDF documents.
- The Templates to comply with for DBT requirement are available on DBTs website only.

For more details see: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/l

FURTHER INFORMATION

DBT contacts:

	T	***************************************	
	Pandemic preparedness and	HORIZON-HLTH-	
	response: Broad spectrum anti-	2023-DISEASE-03-	
	viral therapeutics for infectious	<u>04</u>	
	diseases with epidemic potential		
	Validation of fluid-derived	HORIZON-HLTH-	
	biomarkers for the prediction	2024-DISEASE-03-	
	and prevention of brain	13-two-stage	Dr. Abhishek Singh,
	disorders		3 /
(A)	Pandemic preparedness and	HORIZON-HLTH-	Scientist 'D', DBT
	response: Host-pathogen	2024-DISEASE-08-	icone@dbt.nic.in
	interactions of infectious diseases	<u>20</u>	
	with epidemic potential		
	New detection methods on	HORIZON-CL6-	
	products derived from new	<u>2023-</u>	
	genomic techniques for	FARM2FORK-01-	
	traceability, transparency and	<u>11</u>	
	innovation in the food system		
	Development of smart concepts	HORIZON-CL5-	Dr. Balendra Singh,
	of integrated energy driven bio-	2024-D3-02-03	3 /
(B)	refineries for co-production of		Scientist 'D', DBT
	advanced biofuels, bio-chemicals		balendra.singh@dbt.nic.in
	and biomaterials		

EU Contacts:

• DELEGATION-INDIA-RI@eeas.europa.eu

ANNEX 1: TEMPLATES FOR ADMINISTRATIVE & FINANCIAL CONSIDERATIONS

As this is a fast track procedure, DBT requests Indian Investigator or in the case of more Indian partners in one proposal, the Lead Coordinator-INDIA, to provide information proforma allowing DBT to speed up the granting time, in the interest of quickly staring the research work, as required by the special call for Expressions of Interest.

General Instructions:

- Make sure that all investigators shall thoroughly understand the call text and requirements of participation & funding, before attempting to fill this proforma
- All fields are mandatory. Therefore, all sections of this proforma must be completed. If the space provided is not sufficient, attach additional supporting materials as necessary. Page numbering and headings of any supplementary material must match corresponding sections in filled-in proforma.
- Kindly read the footnotes and furnish information/data, accordingly.
- Each field demands distinct attention, and diligent answer. Therefore, avoid mere replication of information
- Project shall not be pursued if it is incomplete or any of the requirements mentioned herein missing
- To accomplish official considerations, successful proposal(s) shall be asked to submit comprehensive facts about administrative, statutory, ethical and financial considerations (including diligent justification for proposed budgetary requirements).

<u>SR.</u> <u>NO.</u>			<u>PARTICULARS</u>			
1.0		GENERAL INFORMATION				
	1.1	Duration of the Project [Duration of the Project [in months]			
	1.2	Proposed cost of the pr	oject [Cumulative (non-recurring & recurring for recurring	rring), as well	as Segregated	
	1.3	Objectives of the propo- bullet points // NMT 100	sal [only one-two liner, must be interdeper words]	ndent, and to l	pe submitted a	
2.0		Status of EACH of the	INDIAN participating legal entity/organis, as explained in participation modalities .		lfilling various	
		Name of the	ne participating Organization →	Organization 1	Organization 2	
		[Select the one, whichever is applicable]	Public or private university and/or research organization			
			[OR] Private R&D performing institution; Not-for-profit, NGO/ VO/ Trust/ Research foundation			
		[Pl. mark "X" for	Proof of establishment under Indian statue			
		whichever is AVAILABLE	Proof of registration at Gol Public Finance Management System (PFMS)			
			Proof of registration at 'NGO DARPAN' of NITI Aayog			
			Certificate of registration under Society Registration Act			
			<u>VALID</u> SIRO certificate for in-house R&D recognition			

				Audited account statements for the three years Certificate of Incorporation issued	·	
				Companies Act	under	
				Firm's Memorandum of Association		
3.0				NDIAN Project Investigator has vaponsibilities assigned by the consor		accommodate
			•	alid answer for the same with date of	•	_
			no, Provide of T 80 words]	details of precautionary approach	to be followed in case	e of exigency
4.0		WORK DIV	ISION			
	4.1			(s) assigned to EACH participation	ating investigator (In	ndian & EU
		counterparts)) to be involve	ed in this project.		
			AME OF THE VESTIGATOR	PARTICIPATING IN THE CONSORTIUM AS	ORGANIZATION'S ABBREVIATED NAME	ROLE(S) ASSIGNED
				(Project Coordinator/ Lead		
		1		Coordinator-INDIA/CO-PI/CO-I)		
		2				
					<u>'</u>	<u> </u>
		& EU counte	erparts) to be	involved in this project.		
			<u>Sr.</u> NO.	NAME OF THE INVESTIGATOR	RESPONSIBILITIES ASSIGNED	
			NO. 1	NAME OF THE		
	43	Drovida ovn	NO. 1 2	NAME OF THE INVESTIGATOR	ASSIGNED	ndian & FII
	4.3	_	NO. 1 2 Dicit TASK(NAME OF THE INVESTIGATOR (s) assigned to EACH participal	ASSIGNED	ndian & EU
	4.3	_	NO. 1 2 Dicit TASK() to be involved	NAME OF THE INVESTIGATOR (s) assigned to EACH participated in this project.	ASSIGNED ating investigator (In	ndian & EU
	4.3	_	NO. 1 2 Slicit TASK() to be involve Sr. NO. 1	NAME OF THE INVESTIGATOR (s) assigned to EACH participal	ASSIGNED	ndian & EU
	4.3	_	NO. 1 2 Slicit TASK() to be involve Sr. NO.	NAME OF THE INVESTIGATOR (s) assigned to EACH participated in this project. NAME OF THE	ASSIGNED ating investigator (In	ndian & EU
	4.3	counterparts	NO.	NAME OF THE INVESTIGATOR (s) assigned to EACH participated in this project. NAME OF THE INVESTIGATOR	ASSIGNED ating investigator (In	ndian & EU
5.0		counterparts) IMPORTAN	NO.	NAME OF THE INVESTIGATOR (s) assigned to EACH participated in this project. NAME OF THE INVESTIGATOR CTATION & OUTCOME	ASSIGNED ating investigator (In TASKS ASSIGNED	ndian & EU
5.0	5.1	importan How the proj	NO. 1 2 Dicit TASK() to be involve Sr. NO. 1 2 NCE, EXPECT ect relates to	NAME OF THE INVESTIGATOR (s) assigned to EACH participated in this project. NAME OF THE INVESTIGATOR CTATION & OUTCOME India specific and global aspiration	ASSIGNED ating investigator (In TASKS ASSIGNED ?	
5.0		IMPORTAN How the proj Describe brie and the imp	NO. 1 2 Noticit TASK() to be involve Sr. NO. 1 2 NCE, EXPECT ect relates to efly the import pact you expense in short and	NAME OF THE INVESTIGATOR (s) assigned to EACH participated in this project. NAME OF THE INVESTIGATOR CTATION & OUTCOME India specific and global aspiration rance of proposed research & innopect from the project on research d/or long term	ating investigator (In TASKS ASSIGNED) Povation for the scientifich, training and teach	ic community,
5.0	5.1	IMPORTAN How the proj Describe brie and the imp field/disciplin Provide exp	NO. 1 2 Dicit TASK() to be involve Sr. NO. 1 2 NCE, EXPECT ect relates to effly the import and pact you expense in short and dicitly the a	NAME OF THE INVESTIGATOR (s) assigned to EACH participated in this project. NAME OF THE INVESTIGATOR CTATION & OUTCOME India specific and global aspiration rance of proposed research & innopect from the project on research	ating investigator (In TASKS ASSIGNED) TASKS ASSIGNED Evaluation for the scientifich, training and teach assuring country's presented assuring country's presen	ic community, hing in your eparedness in
5.0	5.1 5.2	IMPORTAN How the proj Describe brie and the imp field/disciplin Provide exp mitigating va	NO. 1 2 Sicility TASK(1) to be involved Sr. NO. 1 2 NCE, EXPECT ect relates to effly the import pact you expense in short and olicitly the aurious health extends that while see that while see	NAME OF THE INVESTIGATOR (s) assigned to EACH participated in this project. NAME OF THE INVESTIGATOR CTATION & OUTCOME India specific and global aspiration rance of proposed research & inno spect from the project on research d/or long term anticipated provisions toward en	ating investigator (In TASKS ASSIGNED) Provation for the scientifich, training and teach assuring country's precaused by SARS-CoV-	ic community, thing in your eparedness in 2.

		[In a two page note you should make it clear where your project and state which & how the realistic value will be created overting.]		onea	in ine vai	ue cnai			
0.0		DESCRIBE THE FOLLOWING							
			.I. G.O.	TT.	. 7				
		[Kindly note that the IPR issues need to be in compliance with	the S&	1 agree	ment beti	ween E			
	6.1	provide details of each of the IDs (notant, converight, tradem	orles oto) withi	n the ee	ncortin			
	0.1								
		(<i>including of outsourcing partners</i>) already " PROTECTED ", so far; and commercial ownership of the same (as applicable) which would likely to impact the project under consideration							
	6.2	Provide details of each of the knowhow, models, algorithms	J			chnolos			
		interventions 'within the consortium (including of o				alrea			
		"GENERATED", so far; which would likely to impact the proj			,				
	6.3	Summary of your freedom to operate above mentioned knowledge				ne tenu			
		and beyond the tenure of the project	. ,		U				
.0		BUDGETARY REQUIREMENTS							
	7.1	Details of Consolidated budget proposed							
		(Rs. In lakh							
		Heads	Year	Year	Year	Tota			
			I	II	Ш				
		Equipment(s)							
		Manpower							
		Consumables							
		Travel							
		a. Domestic							
		b. International *							
		i. Expenditure for travel of investigator(s) to EU							
		ii. Expenditure for travel of project staff(s) (preferably							
		registered PhDs and/or Postdocs) to EU							
		iii. Expenditure for stay of investigator(s) in EU							
		iv. Expenditure for stay of project staff(s) (preferably							
		registered PhDs and/or Postdocs) in EU							
		c. Subsistence cost for visiting Indian counterpart							
		investigator(s) and/or project staff(s) within India							
		Contingency Overheads							
		Outsourcing							
		Other (Provide details)							
		Total							
		*The travel of investigator(s) and project staff (s)will be as pe	⊥ r nrevai	ling Go	 vernment	of Ind			
		guidelines	prevai	ung Go	vermmenn	oj ma			
		<i>Suidelines</i>							
		(N.B: Academia can factor in additional sub heads (in other	er categ	ory) su	ch as tro	iining			
		awareness, review meeting, consultancy charges, field & fa	rm exp	enses, e	etc. based	d on t			
		requirement of the project.)							
	7.2	Details of Investigator-wise and/or organization wise & year							
		[Critically review the budget requirements, ensuring every poss		-	_				
		& communication technologies or possibly sharing the		rom alı	ternative	sourc			
		(outsourced) without impacting time and efforts to achieve the g	oal]						
					(Rs.	In lakh			
		Heads	Year	Year	Year	Tota			
			I	II	III				
		Equipment(s)							
		Manpower							

		Consumables
		Travel
		a. Domestic
		b. International*
		i. Expenditure for travel of investigator(s) to EU
		ii. Expenditure for travel of project staff(s) (preferably
		registered PhDs and/or Postdocs) to EU
		iii. Expenditure for stay of investigator(s) in EU
		iv. Expenditure for stay of project staff(s) (preferably
		registered PhDs and/or Postdocs) in EU
		c. Subsistence cost for visiting Indian counterpart
		investigator(s) and/or project staff(s) within India
		Contingency Overheads
		Outsourcing
		Other (Provide details)
		Total
		*The travel of investigator(s) and project staff (s)will be as per prevailing Government of India
		guidelines
		(N.B: Academia can factor in additional sub heads (in other category) such as training &
		awareness, review meeting, consultancy charges, field & farm expenses, etc. based on the
		requirement of the project)
8.0		UNDERTAKING & ENDORSEMENTS
	8.1	a) The research work proposed in the scheme/project entitled "" does not in any way
		duplicate the work already done or being carried out elsewhere on the subject.
		b) Certified that above information is true to the best of our knowledge
		[Name, Signature and Stamp of Lead Coordinator-INDIA (On behalf of all participating
		investigators)]
		<u>Forwarded by</u>
		[Name, Signature & Stamp of Executive Head of Institution/ Organization/ University]
	8.2	Enclose a letter of collaboration and submission of joint proposal (with the project title) from
		Project Coordinator
	8.3	Endorsement by the Head of the legal entity/organization: (to be submitted on letter head in
		support of individual participating investigator of the concerned organization as per the
		proforma placed below)
		Endorsement by the Head of the Organization
		To be submitted on letter head in support of individual participating investigator
		Project Title:
		I. Certified that the institution welcomes participation of
		Dr as the Principal Investigator and
		Dr as the Co-Principal Investigator (Co-PI) or Co-
		Investigator (Co-I) for the project and, in the unforeseen event of discontinuance by the
		Principal Investigator, the Co-PI or Co-I will assume the responsibility of the fruitful
		completion of the project [with due information to the Department of Riotechnology (DRT)]

II. Certified that all resources (infrastructure, techno-scientific, administrative, etc.) as per the terms and conditions of the grant, will be extended to investigator(s) throughout the duration of the project.

III. Organization assumes to undertake the financial and other management responsibilities of the project.

IV. Certified that comprehensive appraisal pertaining to administrative, financial, ethical, regulatory & statutory requirements has been made towards participation of this organization through this project, beforehand.

V. We thoroughly understood the modalities of participation & funding, and shall abide to it.

VI. We hereby commit to obtain all applicable (central & state) environmental, regulatory & statutory as well as local governmental authorizations, prior to the commencement of relevant research, innovation & translation activities.

VII. We agree to accept the terms and conditions of Department of Biotechnology, Govt. Of India.

VIII. The details & information given in the project proposal are true & factual.


Date:	
Date.	Name & Signature with Stamp
	of Head of the Organization
Place:	

ANNEX 2: HOW TO ACCESS HORIZON EUROPE PORTAL & FORMALITIES

How to Participate:

By selecting the "<u>How to Participate</u>" tab on the Horizon Europe Funding & Tenders Portal "Home" page, researchers and innovators will be directed to a page that provides easy access and instructions for using key parts of the portal (see screen shot below):

- Create an Account
- > Register an Organization
- > Find Partners
- > Find a Call for Proposals
- > Submit a Proposal



ANNEX 3: FINDING PARTNERS

The starting point is to consider partners with whom you already have direct or indirect connections. As participation in a Horizon Europe call requires an interdisciplinary and/or inter-sectoral approach for a challenge to be addressed appropriately, it may become necessary to look for partners outside the usual circle of contacts.

Hereunder you will find a list of European services that assist in finding the right partners:

Partner search tools	Partner search tools						
Partner Search for organisation profiles on the EC platform	Find partners for your project ideas among the organisations registered in the <u>Funding & Tenders Portal</u> of the European Commission.						
Find partners with the help of Enterprise Europe Network	The <u>Enterprise Europe Network</u> online database contains over 2,500 technology profiles (offers and requests) from companies and R&D organisations from over 60 countries in Europe and beyond.						
Guide to an adequate partner search	Horizon Europe: Guide to an adequate partner search						
Expressed Interest	Horizon Europe Funding & Tenders Portal: search by call topics where organisations have participated or expressed interest in participating in the future.						
euMatch 2.0	Partner Search and Matchmaking platform to find partners and project initiatives to participate in H2020 supported health related projects.						
NCP Network	National Contact Points for Horizon Europe						